These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35285286)

  • 1. Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma.
    Yan JQ; Liu M; Ma YL; Le KD; Dong B; Li GH
    Exp Biol Med (Maywood); 2022 Jun; 247(11):910-920. PubMed ID: 35285286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
    Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
    Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
    Shu T; Li Y; Wu X; Li B; Liu Z
    Cancer Lett; 2017 Dec; 411():65-73. PubMed ID: 28989055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer.
    Silva VL; Saxena J; Nicolini F; Hoare JI; Metcalf S; Martin SA; Lockley M
    Cell Death Dis; 2021 Apr; 12(4):395. PubMed ID: 33854036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.
    Gillet JP; Calcagno AM; Varma S; Davidson B; Bunkholt Elstrand M; Ganapathi R; Kamat AA; Sood AK; Ambudkar SV; Seiden MV; Rueda BR; Gottesman MM
    Clin Cancer Res; 2012 Jun; 18(11):3197-206. PubMed ID: 22492981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.
    Osterberg L; Levan K; Partheen K; Delle U; Olsson B; Sundfeldt K; Horvath G
    BMC Cancer; 2009 Oct; 9():368. PubMed ID: 19835627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
    Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
    Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
    Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
    Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
    Zhan SJ; Liu B; Linghu H
    Oncol Rep; 2018 Jun; 39(6):2653-2663. PubMed ID: 29693178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FANCD2 expression affects platinum response and further characteristics of high grade serous ovarian cancer in cells with different genetic backgrounds.
    Taylor SJ; Hollis RL; Gourley C; Herrington CS; Langdon SP; Arends MJ
    Exp Mol Pathol; 2024 Aug; 138():104916. PubMed ID: 38959632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific copy number alterations associated with docetaxel/carboplatin response in ovarian carcinomas.
    Osterberg L; Levan K; Partheen K; Delle U; Olsson B; Sundfeldt K; Horvath G
    Anticancer Res; 2010 Nov; 30(11):4451-8. PubMed ID: 21115892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
    Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
    Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
    Liblab S; Vusuratana A; Areepium N
    Asian Pac J Cancer Prev; 2020 Jul; 21(7):1925-1929. PubMed ID: 32711417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
    Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
    Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.
    Brozovic A; Duran GE; Wang YC; Francisco EB; Sikic BI
    Mol Oncol; 2015 Oct; 9(8):1678-93. PubMed ID: 26025631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
    Hoare JI; Hockings H; Saxena J; Silva VL; Haughey MJ; Wood GE; Nicolini F; Mirza H; McNeish IA; Huang W; Maniati E; Graham TA; Lockley M
    Gynecol Oncol; 2022 Oct; 167(1):96-106. PubMed ID: 35918200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.